Johnson & Johnson
Johnson & Johnson Appoints Daniel Pinto to Board of Directors
Summary
Johnson & Johnson announced on June 10, 2025, that Daniel Pinto has been elected to its Board of Directors, effective July 1, 2025. Mr. Pinto, currently President of JPMorganChase, will serve on the Audit and Compensation & Benefits Committees. He will receive compensation as outlined in the Company's 2025 Proxy Statement. JPMorganChase, a key banking service provider to Johnson & Johnson, received approximately $39.2 million from the Company in fiscal year 2024 for various banking services.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement